One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Individualized Local Recurrence Estimates for Ductal Carcinoma In Situ.
doi : 10.1200/JCO.24.00962
Volume 42(27) pgs. 3167-3262 September 20, 2024
Emerging Therapies for the Management of Human Epidermal Growth Factor Receptor 2-/ERBB2-Altered Advanced Biliary Tract Cancers.
Zeme, Emily L. BS 1; Van Loon, Katherine MD, MPH 1,2,,; Kelley, Robin K. MD 1,2,; Gordan, John D. MD, PhD 1,2,
doi : 10.1200/JCO.24.00868
Lymphoma Classifications, How to Develop a Future Unified Taxonomy.
Campo, Elias MD 1,; Dierickx, Daan MD 2,; Dirnhofer, Stefan MD 3,; Dunleavy, Kieron MD 4,; Gaulard, Philippe MD 5,; Hasserjian, Robert P. MD 6,; Jaffe, Elaine S. MD 7,; Kim, Won Seog MD 8,; King, Rebecca L. MD 9; Lim, Megan S. MD 10,; Ott, German MD 11; Piris, Miguel A. MD 12,,; Salles, Gilles MD 13,; Siebert, Reiner MD 14,
doi : 10.1200/JCO.24.00070
Navigating Change in Tumor Naming: Exploring the Complexities and Considerations of Shifting Toward Molecular Classifications.
Ilie, Marius MD, PhD 1,,; Heeke, Simon PhD 2,; Horgan, Denis PhD 3; Hofman, Paul MD, PhD 1,
doi : 10.1200/JCO.24.00323
Durability of Response With Selpercatinib in Patients With RET-Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001.
Wirth, Lori J. MD 1,; Brose, Marcia S. MD 2,; Subbiah, Vivek MD 3,4,; Worden, Francis MD 5,; Solomon, Ben MD 6,; Robinson, Bruce MD 7,; Hadoux, Julien MD 8,; Tomasini, Pascale MD 9,; Weiler, Daniela MD 10,; Deschler-Baier, Barbara MD 11,; Tan, Daniel S.W. MD 12,13,; Maeda, Patricia MD 14,; Lin, Yan PhD 14,; Singh, Ravinder PhD 14,; Bayt, Theresa MD 14,; Drilon, Alexander MD 15,; Cassier, Philippe A. MD 16,,
doi : 10.1200/JCO.23.02503
Molecular Expression Assays Improve the Prediction of Local and Invasive Local Recurrence After Breast-Conserving Surgery for Ductal Carcinoma In Situ.
Hahn, Ezra MD 1,2; Sutradhar, Rinku PhD 3,4; Paszat, Lawrence MD 2,3,4,5; Nguyen, Lena MSc 3; Rodin, Danielle MD 1,2,; Nofech-Mozes, Sharon MD 6,7; Trebinjac, Sabina BSc 5; Jerzak, Katarzyna J. MD 8,; Fong, Cindy BSc 3; Rakovitch, Eileen MD, FRCPC 2,3,5,,
doi : 10.1200/JCO.23.02276
Trastuzumab Deruxtecan in Human Epidermal Growth Factor Receptor 2-Expressing Biliary Tract Cancer (HERB; NCCH1805): A Multicenter, Single-Arm, Phase II Trial.
Ohba, Akihiro MD 1,; Morizane, Chigusa MD, PhD 1,,; Kawamoto, Yasuyuki MD, PhD 2,; Komatsu, Yoshito MD, PhD 2,; Ueno, Makoto MD, PhD 3,; Kobayashi, Satoshi MD 3,; Ikeda, Masafumi MD, PhD 4,; Sasaki, Mitsuhito MD 4; Furuse, Junji MD, PhD 3,5,; Okano, Naohiro MD, PhD 5,; Hiraoka, Nobuyoshi MD, PhD 6; Yoshida, Hiroshi MD, PhD 6; Kuchiba, Aya PhD 7,; Sadachi, Ryo PhD 7; Nakamura, Kenichi MD, PhD, MBA 8,; Matsui, Naoko BS 8; Nakamura, Yoshiaki MD, PhD 9,; Okamoto, Wataru MD, PhD 10,; Yoshino, Takayuki MD, PhD 9,; Okusaka, Takuji MD, PhD 1,
doi : 10.1200/JCO.23.02010
Bevacizumab Erlotinib Switch Maintenance in Chemo-Responsive Advanced Gallbladder and Cholangiocarcinoma (BEER BTC): A Multicenter, Open-Label, Randomized, Phase II Trial.
Ramaswamy, Anant MD, DM 1; Bhargava, Prabhat MD, DM 1,; Srinivas, Sujay MD, DM 1,; Kapoor, Akhil MD, DM 2,; Mishra, Bal Krishna MD 2; Gupta, Anuj MD 2; Mandavkar, Sarika BSc 1; Kannan, Sadhana MSc 3; Chaugule, Deepali BSc 4; Patil, Rajshree BSc 4; Parulekar, Manali BSc 1; Nashikkar, Chaitali BHMS 5; Ankathi, Suman Kumar MD 6; Kaushal, Rajiv Kumar MD 7; Naughane, Deepali BDS 1; Daddi, Anuprita MD 8; Mer, Neha MSc 4; Shetty, Nitin MD 6; Ostwal, Vikas MD 9,,
doi : 10.1200/JCO.23.02420
Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With ERBB2/3 Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.
Cannon, Timothy L. MD 1,; Rothe, Michael MS 2; Mangat, Pam K. MS 2,; Garrett-Mayer, Elizabeth PhD 2; Chiu, Vi K. MD, PhD 3,; Hwang, Jimmy MD, FACP 4,; Vijayvergia, Namrata MD 5,; Alese, Olatunji B. MD 6,; Dib, Elie G. MD 7; Duvivier, Herbert L. MD 8,; Klute, Kelsey A. MD 9,; Sahai, Vaibhav MBBS, MS 10,; Ahn, Eugene R. MD 11; Bedano, Pablo MD 12,; Behl, Deepti MD 13,; Sinclair, Sarah DO 14; Thota, Ramya MBBS 15; Urba, Walter J. MD, PhD 16,; Yang, Eddy S. MD, PhD 17,; Grantham, Gina N. BS 2; Hinshaw, Dominique C. PhD 2; Gregory, Abigail MPH 2,; Halabi, Susan PhD, FASCO, FASA, FSCT 18,; Schilsky, Richard L. MD, FACP, FSCT, FASCO 2,
doi : 10.1200/JCO.23.02078
Association Between State Medicaid Policies and Accrual of Black or Hispanic Patients to Cancer Clinical Trials.
Schpero, William L. PhD 1,2,,; Takvorian, Samuel U. MD, MSHP 3,4,5,; Blickstein, Daniel MS 6,; Shafquat, Afrah PhD 6,; Liu, Jingshu MFin, MS 6,; Chatterjee, Arnaub K. MHA, MPA 7,; Lamont, Elizabeth B. MD, MS, MMSc 6,; Chatterjee, Paula MD, MPH 4,5,
doi : 10.1200/JCO.23.01149
Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance.
Mateos, Maria-Victoria MD, PhD 1,,; Martinez-Lopez, Joaquin MD, PhD 2,; Rodriguez Otero, Paula MD, PhD 3,; Gonzalez-Calle, Veronica MD, PhD 4,5,; Gonzalez, Marta Sonia MD 6,; Oriol, Albert MD 7,; Gutierrez, Norma C. MD, PhD 8,9,10,; Rios-Tamayo, Rafael MD, PhD 11,; Rosinol, Laura MD, PhD 12,; Alvarez Rivas, Miguel Angel PhD 13,; Bargay, Joan MD, PhD 14,; Gonzalez-Rodriguez, Ana Pilar MD, PhD 15,; Alegre, Adrian MD 16,; Escalante, Fernando MD 17,; Inigo Rodriguez, Maria Belen MD 18; De La Rubia, Javier MD, PhD 19,20,21,; Teruel, Ana Isabel MD, PhD 22; de Arriba, Felipe MD 23,; Palomera, Luis MD, PhD 24,; Hernandez, Miguel T. MD, PhD 25; Lopez Jimenez, Javier MD, PhD 26,; Reinoso-Segura, Marta MD 27,; Garcia Mateo, Aranzazu MD, PhD 28; Ocio, Enrique M. MD, PhD 29,; Paiva, Bruno MD, PhD 30,; Puig, Noemi MD, PhD 31,; Cedena, M. Teresa MD, PhD 32,; Blade, Joan MD 33,; Lahuerta, Juan Jose MD, PhD 34,; San-Miguel, Jesus F. MD, PhD 35,; on behalf of the Spanish Myeloma Group (GEM-Pethema)
doi : 10.1200/JCO.23.02771
It Mattered Later: A Patient-Turned-Doctor's Perspective on Fertility Loss.
Cupit-Link, Margaret MD 1,,
doi : 10.1200/JCO.24.00491
Comprehensive Discussions on KIT ATP-Binding Pocket/Activation Loop Mutations in Ripretinib Resistance.
Xia, Yanzhe MSc; Zhang, Xinhua MD
doi : 10.1200/JCO.24.00673
Reply to Y. Xia et al.
Bauer, Sebastian MD; Fletcher, Jonathan A. MD; Rauh, Daniel PhD; Falkenhorst, Johanna MD; Muhlenberg, Thomas PhD
doi : 10.1200/JCO.24.00942
Erratum: Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial.
doi : 10.1200/JCO-24-01660
Erratum: Blinatumomab for First-Line Treatment of Children and Young Persons With B-ALL.
doi : 10.1200/JCO-24-01672
